Sarah Childs

Dr. Sarah Childs

Pronouns: She/her



Cumming School of Medicine, Department of Biochemistry and Molecular Biology

Child Health & Wellness Researcher

Alberta Children's Hospital Research Institute


Associate Member

Arnie Charbonneau Cancer Institute

Full Member

Libin Cardiovascular Institute

Contact information

Web presence

Phone number

Office: 403.220.8277
Lab: 403.220.3090


Office: HSC2223

For media enquiries, contact

Kelly Johnston
Senior Communications Specialist

Please submit your media request here


Preferred method of communication


Leslie McGill


Office: 403.220.4483


Educational Background

B.S. Biochemistry, University of Toronto, 1989

Doctor of Philosophy Biological Sciences, University of Toronto, 1995

M.S. Biological Sciences, University of Toronto, 1992


Dr. Childs obtained her undergraduate education at the University of Toronto in biochemistry before undertaking graduate work with Dr. Victor Ling in the Department of Medical Biophysics at the University of Toronto in molecular cancer biology. For postdoctoral work she continued her work in cancer biology at the British Columbia Cancer Research, but then moved to work on the development of blood vessels in the zebrafish model, working with Mark Fishman at the Cardiovascular Research Centre of Massachusetts General Hospital at Harvard University. Since 2001 she has been in the Department of Biochemistry and Molecular Biology at the University of Calgary where she studies the genetics of patterning and stabilization of blood vessels.


Areas of Research

Area of Focus
  • Cardiovascular
  • Developmental Genetics
  • Model Organism
  • Tissue Regeneration
  • Genetics of blood vessel patterning and stabilization
Summary of Research

We are interested in angiogenesis, the process by which new blood vessels develop. Blood vessels first develop as naked endothelial tubes, and then acquire a coating of ‘mural’ cells (either smooth muscle cells or pericytes). Dysfunctional vessels underlie a large number of serious diseases. We focus on using developmental biology to tease out the signals that grow and stabilize new blood vessels as a means to potential therapy for blood vessel disorders.

Project in vascular patterning:

Blood vessels are customized for delivery of oxygen and nutrients to different organs with different architectures and metabolic needs. How do blood vessels acquire organ-specific patterns? In this project we examine the normal patterning of blood vessels during development and the molecular pathways that control their pattern. We also examine the role of patterning genes such as the PlexinD1 receptor to determine how it guides vascular development using genetic analysis of ligands and signaling pathways. We have a strong interest in GTPase control of the actin cytoskeleton in vascular development, and their particular roles in diseases such as vascular malformation.

Project in vascular stabilization:

The origins of mural cells are not well understood. In the head, mural cells are thought to originate in neural crest cells, but how do they migrate to specific vessels and what signals allow them to contact and ensheath endothelial cells? In this project we examine the genetic control of mural cell development. Using transgenic smooth muscle and pericyte marker lines we trace mural cell migration in real time. Loss of mural cell attachment to endothelial cells results in brain hemorrhage. We have developed mutant animals with defective vascular stabilization that are models of both hemorrhagic and ischemic stroke.

Project in microRNA control of smooth muscle differentiation:

MicroRNAs are small RNAs that exert control by binding to mRNAs and blocking translation. We have demonstrated the role of several microRNAs on smooth muscle maturation. In this project, we are exploring how single microRNAs control multiple target genes to control development. We are also exploring how multiple microRNAs impinge on the same target mRNA to finely tune its expression.

Precision medicine using the zebrafish:

A number of rare genetic disorders are due to mutations in novel genes. We use the zebrafish to determine whether mutations in some of these unknown novel genes causes disease by making zebrafish knockout models using CRISPR mutagenesis and examining their phenotype. We can also use these models to develop possible therapeutic strategies. We are supported by the CIRH Rare Diseases Models and Mechanisms Network for this work.

The zebrafish model:

We use zebrafish as a model system because as a vertebrate, their cardiovascular system is very similar to that of mammals. Furthermore, there is close similarity from a genetic point of view. To date, genes that have been found to be important for zebrafish vascular development have also been found to be important for human or mouse vascular development. Zebrafish are a common tropical fish which develop as transparent, externally fertilized embryos. We can observe their development during all stages of embryogenesis under a microscope. This allows us to do very detailed screens for subtle genetic defects, and is in contrast to mammals which develop in utero and are inaccessible. The capacity for live confocal imaging of development using this model is outstanding.

Participation in university strategic initiatives